Outcomes prioritized by the ASH Guideline Panel on Cardiopulmonary and Kidney Disease
| Critical outcomes for decision-making . |
|---|
| Q1. |
| • Test accuracy of ECHO to diagnose PH compared with cardiac catheterization |
| • Mortality |
| • Change in patient management |
| • Patient desire to know about abnormal screening |
| • Rate of cardiac catheterization |
| • Anxiety related to abnormal test |
| Q2. |
| • Appropriate treatment in appropriate patients |
| • Mortality |
| • Time to diagnosis |
| • Complications related to cardiac catheterization (eg, bleeding, clots, infection, arrhythmia, and pain) |
| • Progression of cardiac dysfunction |
| Q3. |
| • Mortality |
| • Quality of life |
| • PH therapy side effects (eg, hypotension, flushing/headache, injection-related pain, liver dysfunction) |
| • Oxygen requirement |
| • Dyspnea, exercise tolerance, 6MWD, and NYHA functional class |
| • Transfusion side effects (eg, alloimmunization, need for and complications related to IV access, iron overload) |
| • Change in pain episodes |
| • Burden of treatment |
| • Cardiac function |
| • Hospitalization rate |
| • Syncope |
| Q4. |
| • Rate of cardiac catheterization |
| • Mortality |
| • Change in patient management |
| • Patient desire to know about abnormal screening |
| • Anxiety related to abnormal test |
| Q5. |
| • Quality of life |
| • Mortality |
| • Cardiovascular outcomes |
| • Acute and chronic pain rate |
| • Acute chest syndrome rate |
| • Nocturnal enuresis |
| • Priapism |
| • Burden of treatment |
| • Patient desire to know about abnormal screening |
| Q6. |
| • End-stage renal disease |
| • Mortality |
| • Quality of life/function |
| • Burden of treatment |
| • Worsening proteinuria |
| • Hospitalization rate |
| • Hyperkalemia |
| • Hypotension |
| • Acute kidney injury |
| Q7. |
| • Overall mortality |
| • Transplant organ survival |
| • Quality of life |
| • Transplant-related mortality |
| • Treatment burden related to transplant vs dialysis |
| • Improvement in anemia |
| • Hospitalization |
| • Pain episodes |
| Q8. |
| • Mortality |
| • Quality of life |
| • Improvement in renal function |
| • Improvement in hemoglobin |
| • Acute and chronic pain rate |
| • Burden of treatment |
| • Bone marrow suppression |
| • Hypertension |
| • Thrombosis |
| Q9. |
| • Mortality |
| • Stroke |
| • Cardiovascular events |
| • Worsening renal function |
| • Quality of life/function |
| • Hypotension |
| • Burden of treatment (eg, emergency department visits, adherence, monitoring) |
| • Medication side effects |
| • Hospitalization rate |
| Q10. |
| • Major bleeding |
| • Risk of recurrent pulmonary embolism |
| • Risk of recurrent deep vein thrombosis |
| • Quality of life |
| • Mortality |
| • SCD-related complications |
| • Treatment burden |
| • Postthrombotic syndrome |
| Critical outcomes for decision-making . |
|---|
| Q1. |
| • Test accuracy of ECHO to diagnose PH compared with cardiac catheterization |
| • Mortality |
| • Change in patient management |
| • Patient desire to know about abnormal screening |
| • Rate of cardiac catheterization |
| • Anxiety related to abnormal test |
| Q2. |
| • Appropriate treatment in appropriate patients |
| • Mortality |
| • Time to diagnosis |
| • Complications related to cardiac catheterization (eg, bleeding, clots, infection, arrhythmia, and pain) |
| • Progression of cardiac dysfunction |
| Q3. |
| • Mortality |
| • Quality of life |
| • PH therapy side effects (eg, hypotension, flushing/headache, injection-related pain, liver dysfunction) |
| • Oxygen requirement |
| • Dyspnea, exercise tolerance, 6MWD, and NYHA functional class |
| • Transfusion side effects (eg, alloimmunization, need for and complications related to IV access, iron overload) |
| • Change in pain episodes |
| • Burden of treatment |
| • Cardiac function |
| • Hospitalization rate |
| • Syncope |
| Q4. |
| • Rate of cardiac catheterization |
| • Mortality |
| • Change in patient management |
| • Patient desire to know about abnormal screening |
| • Anxiety related to abnormal test |
| Q5. |
| • Quality of life |
| • Mortality |
| • Cardiovascular outcomes |
| • Acute and chronic pain rate |
| • Acute chest syndrome rate |
| • Nocturnal enuresis |
| • Priapism |
| • Burden of treatment |
| • Patient desire to know about abnormal screening |
| Q6. |
| • End-stage renal disease |
| • Mortality |
| • Quality of life/function |
| • Burden of treatment |
| • Worsening proteinuria |
| • Hospitalization rate |
| • Hyperkalemia |
| • Hypotension |
| • Acute kidney injury |
| Q7. |
| • Overall mortality |
| • Transplant organ survival |
| • Quality of life |
| • Transplant-related mortality |
| • Treatment burden related to transplant vs dialysis |
| • Improvement in anemia |
| • Hospitalization |
| • Pain episodes |
| Q8. |
| • Mortality |
| • Quality of life |
| • Improvement in renal function |
| • Improvement in hemoglobin |
| • Acute and chronic pain rate |
| • Burden of treatment |
| • Bone marrow suppression |
| • Hypertension |
| • Thrombosis |
| Q9. |
| • Mortality |
| • Stroke |
| • Cardiovascular events |
| • Worsening renal function |
| • Quality of life/function |
| • Hypotension |
| • Burden of treatment (eg, emergency department visits, adherence, monitoring) |
| • Medication side effects |
| • Hospitalization rate |
| Q10. |
| • Major bleeding |
| • Risk of recurrent pulmonary embolism |
| • Risk of recurrent deep vein thrombosis |
| • Quality of life |
| • Mortality |
| • SCD-related complications |
| • Treatment burden |
| • Postthrombotic syndrome |